IMMUNOHISTOCHEMICAL EXPRESSION OF MYELOID CELL  LEUKEMIA-1 AND ITS CORRELATION WITH ER, PR, HER 2-NEU +/-  CASES OF CARCINOMA BREAST

Dr. Shilpi Patel, Dr. Nishi Tandon, Dr. Andleeb Zehra, Dr. Farheen Khan, Dr. Sharique Ahmad, Dr.NirupmaLal

doi:10.55529/ijprt.1083

IMMUNOHISTOCHEMICAL EXPRESSION OF MYELOID CELL LEUKEMIA-1 AND ITS CORRELATION WITH ER, PR, HER 2-NEU +/- CASES OF CARCINOMA BREAST

Authors

Dr. Shilpi Patel, Dr. Nishi Tandon, Dr. Andleeb Zehra, Dr. Farheen Khan, Dr. Sharique Ahmad, Dr.NirupmaLal

DOI:

https://doi.org/10.55529/ijprt.1083

Keywords:

Breast carcinoma, clinical stage, immunohistochemistry, Myeloid cell leukemia-1 (MCL-1), prognostic biomarker

Abstract

Background & Objectives: Breast carcinoma, the foremost typical cancer and fatal causeamong women worldwide, is marked by unrestrained growth of breast epithelial cells.It’sprognosis depends on biomarkers including Progesterone Receptor (PR), HER2-neu and Estrogen Receptor (ER). Myeloid cell leukemia

References

Ali S, Coombes RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer. 2002;2(2):101-12.

Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009;9(9):631-43.

Downloads

Published

2025-10-15

How to Cite

Dr. Shilpi Patel, Dr. Nishi Tandon, Dr. Andleeb Zehra, Dr. Farheen Khan, Dr. Sharique Ahmad, Dr.NirupmaLal. (2025). IMMUNOHISTOCHEMICAL EXPRESSION OF MYELOID CELL LEUKEMIA-1 AND ITS CORRELATION WITH ER, PR, HER 2-NEU +/- CASES OF CARCINOMA BREAST. International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 2521–2529. https://doi.org/10.55529/ijprt.1083